These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 33738839)

  • 41. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
    Kong J; Kong F; Gao J; Zhang Q; Dong S; Gu F; Ke S; Pan B; Shen Q; Sun H; Zheng L; Sun W
    Mol Cancer; 2014 Jan; 13():7. PubMed ID: 24418169
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.
    Liu Y; Liu A; Li H; Li C; Lin J
    Cancer Prev Res (Phila); 2011 Aug; 4(8):1296-305. PubMed ID: 21490132
    [TBL] [Abstract][Full Text] [Related]  

  • 43. STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC.
    Han Q; Wang Y; Pang M; Zhang J
    J Exp Clin Cancer Res; 2017 Nov; 36(1):156. PubMed ID: 29115974
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo and in vitro effects of microRNA-221 on hepatocellular carcinoma development and progression through the JAK-STAT3 signaling pathway by targeting SOCS3.
    Huang S; Zhou D; Li YX; Ming ZY; Li KZ; Wu GB; Chen C; Zhao YN
    J Cell Physiol; 2019 Apr; 234(4):3500-3514. PubMed ID: 30370582
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual functions of STAT3 in LPS-induced angiogenesis of hepatocellular carcinoma.
    Wang Z; Yan M; Li J; Long J; Li Y; Zhang H
    Biochim Biophys Acta Mol Cell Res; 2019 Apr; 1866(4):566-574. PubMed ID: 30521872
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
    Sia D; Jiao Y; Martinez-Quetglas I; Kuchuk O; Villacorta-Martin C; Castro de Moura M; Putra J; Camprecios G; Bassaganyas L; Akers N; Losic B; Waxman S; Thung SN; Mazzaferro V; Esteller M; Friedman SL; Schwartz M; Villanueva A; Llovet JM
    Gastroenterology; 2017 Sep; 153(3):812-826. PubMed ID: 28624577
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
    Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
    Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quercetin exerts anti-tumor immune mechanism by regulating IL-6/JAK2/STAT3 signaling pathway to deplete Treg cells.
    Liao Y; Xie X; Zhang C; Zhong H; Shan L; Yu P; Xu L
    Toxicon; 2024 May; 243():107747. PubMed ID: 38714236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.
    He Q; Liu M; Huang W; Chen X; Zhang B; Zhang T; Wang Y; Liu D; Xie M; Ji X; Sun M; Tian D; Xia L
    Hepatology; 2021 Dec; 74(6):3174-3193. PubMed ID: 34288020
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interleukin-8 Induces Expression of FOXC1 to Promote Transactivation of CXCR1 and CCL2 in Hepatocellular Carcinoma Cell Lines and Formation of Metastases in Mice.
    Huang W; Chen Z; Zhang L; Tian D; Wang D; Fan D; Wu K; Xia L
    Gastroenterology; 2015 Oct; 149(4):1053-67.e14. PubMed ID: 26065367
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Liver cancer in ovo models for preclinical testing.
    Garcia P; Wang Y; Viallet J; Mehdi NEH; Montaut E; Decaens T; Emadali A; Macek Jílková Z
    FASEB J; 2024 Sep; 38(17):e70029. PubMed ID: 39215630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antitumor effects of Stat3-siRNA and endostatin combined therapies, delivered by attenuated Salmonella, on orthotopically implanted hepatocarcinoma.
    Jia H; Li Y; Zhao T; Li X; Hu J; Yin D; Guo B; Kopecko DJ; Zhao X; Zhang L; Xu DQ
    Cancer Immunol Immunother; 2012 Nov; 61(11):1977-87. PubMed ID: 22527247
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IL-17 Activates the IL-6/STAT3 Signal Pathway in the Proliferation of Hepatitis B Virus-Related Hepatocellular Carcinoma.
    Hu Z; Luo D; Wang D; Ma L; Zhao Y; Li L
    Cell Physiol Biochem; 2017; 43(6):2379-2390. PubMed ID: 29073625
    [TBL] [Abstract][Full Text] [Related]  

  • 56. miR-570 Inhibits Proliferation, Angiogenesis, and Immune Escape of Hepatocellular Carcinoma.
    Lin Y; Liu S; Su L; Su Q; Lin J; Huang X; Wang C
    Cancer Biother Radiopharm; 2018 Aug; 33(6):252-257. PubMed ID: 29874097
    [TBL] [Abstract][Full Text] [Related]  

  • 57. miR-515-5p suppresses HCC migration and invasion via targeting IL6/JAK/STAT3 pathway.
    Ni JS; Zheng H; Ou YL; Tao YP; Wang ZG; Song LH; Yan HL; Zhou WP
    Surg Oncol; 2020 Sep; 34():113-120. PubMed ID: 32891315
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long non-coding RNA UBE2CP3 enhances HCC cell secretion of VEGFA and promotes angiogenesis by activating ERK1/2/HIF-1α/VEGFA signalling in hepatocellular carcinoma.
    Lin J; Cao S; Wang Y; Hu Y; Liu H; Li J; Chen J; Li P; Liu J; Wang Q; Zheng L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):113. PubMed ID: 29866133
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SUMOylation inhibitors activate anti-tumor immunity by reshaping the immune microenvironment in a preclinical model of hepatocellular carcinoma.
    Wang Z; Pan B; Su L; Yu H; Wu X; Yao Y; Zhang X; Qiu J; Tang N
    Cell Oncol (Dordr); 2024 Apr; 47(2):513-532. PubMed ID: 38055116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
    Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
    World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.